The role of domain alterations in F1Fo-ATPase dysfunction associated to neurodegenerative diseases
Ageing and Neurodegenerative Diseases · 2023
DOI: 10.20517/and.2022.28 ↗Kurz gefasst
Fachartikel in der Zeitschrift Ageing and Neurodegenerative Diseases, 2023. Verfasst von Miaomiao Zhou und 10 weiteren Autor:innen. Die Arbeit wurde bisher 3-mal zitiert (Crossref).
Abstract (Originalsprache)
Mitochondrial dysfunction can lead to degeneration in the central nervous system. F1Fo-ATPase catalyzes most of the intracellular ATP synthesis which plays an essential role in cellular energy supply. The dimerized assembly of F1Fo-ATPase underlies the rotational catalytic function and regulates the mechanisms of oxidative phosphorylation. F1Fo-ATPase dysfunction is involved in a variety of neurological diseases, including epilepsy, Alzheimer's disease, and Parkinson’s disease. Dysregulated expression, activity, and localization of F1Fo-ATPase subunits and the interactions with pathogenic proteins result in decreased F1Fo-ATPase activity and ATP production, and aggravated oxidative stress.
Zitieren
APA
Zhou, M., Lin, Y., Zhang, Z., Tang, Y., Zhang, W., Liu, H., Peng, G., Qiu, J., Guo, W., Chen, X., & Xu, P. (2023). The role of domain alterations in F1Fo-ATPase dysfunction associated to neurodegenerative diseases. Ageing and Neurodegenerative Diseases. https://doi.org/10.20517/and.2022.28
Vancouver
Zhou M, Lin Y, Zhang Z, Tang Y, Zhang W, Liu H, et al. The role of domain alterations in F1Fo-ATPase dysfunction associated to neurodegenerative diseases. Ageing and Neurodegenerative Diseases. 2023. doi:10.20517/and.2022.28
BibTeX
@article{Zhou2023,
author = {Zhou, Miaomiao and Lin, Yuwan and Zhang, Zhiling and Tang, Yuting and Zhang, Wenlong and Liu, Hanqun and Peng, Guoyou and Qiu, Jiewen and Guo, Wenyuan and Chen, Xiang and Xu, Pingyi},
title = {The role of domain alterations in F1Fo-ATPase dysfunction associated to neurodegenerative diseases},
journal = {Ageing and Neurodegenerative Diseases},
year = {2023},
doi = {10.20517/and.2022.28}
}
EUVIMED